Vaccines and the Trump Administration

4 April 2017 - Writing recently in the New York Times, infectious disease physician Peter Hotez warned: “It’s looking as ...

Read more →

U.S. FDA accepts for priority review Bristol-Myers Squibb’s application for Opdivo (nivolumab) in previously treated dMMR or MSI-H metastatic colorectal cancer

4 April 2017 - Application based on results from Phase 2 CheckMate-142 study. ...

Read more →

AbbVie announces Ibrutinib (Imbruvica) supplemental new drug application for previously treated chronic graft-versus-host-disease accepted for review by U.S. FDA

4 April 2017 - AbbVie today announced a supplemental new drug application was accepted for review by the U.S. FDA for ...

Read more →

AB2 Bio’s tadekinig alfa therapy receives breakthrough therapy designation from the US FDA for the treatment of monogenic, interleukin-18 associated auto-inflammatory conditions with ongoing systemic inflammation

3 April 2017 - Breakthrough therapy designation recognises the major potential therapeutic benefits of tadekinig alfa in the treatment of ...

Read more →

Teva Announces FDA approval of Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease

3 April 2017 - Approval represents the first new treatment option for chorea associated with Huntington’s disease in nearly a ...

Read more →

Jazz Pharmaceuticals completes rolling submission of new drug application for Vyxeos (CPX-351), an investigational treatment for acute myeloid leukaemia

3 April 2017 - Jazz Pharmaceuticals today announced the completion on 31 March 2017 of a rolling submission of a new ...

Read more →

The nominee to run America’s drug regulator is a sound choice

1 April 2017 - Scott Gottlieb is close to the pharma industry but knows its tactics. ...

Read more →

Ibrance (palbociclib) receives FDA regular approval and expanded indication for first-line HR+, HER2- metastatic breast cancer

31 March 2017 - Pfizer today announced that the U.S. FDA has approved a supplemental new drug application for its first-in-class ...

Read more →

Kite completes submission of U.S. biologics license application for axicabtagene ciloleucel as the first CAR-T therapy for the treatment of patients with aggressive non-Hodgkin lymphoma

31 March 2017 - Kite is preparing for potential approval and launch for axicabtagene ciloleucel in 2017. ...

Read more →

Aura Biosciences announces initiation of Phase 1b clinical trial and receipt of FDA fast track designation for AU-011 for the treatment of primary ocular melanoma

30 March 2017 - First patient dosed with light-activated AU-011 at Wills Eye Hospital in Philadelphia. ...

Read more →

Akari Therapeutics announces FDA fast track designation for Coversin

30 March 2017 - Akari Therapeutics announced today that the US FDA has granted fast track designation for Coversin for treatment ...

Read more →

Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the US

29 March 2017 - Novo Nordisk today announced that the company has resubmitted the new drug application for fast-acting insulin ...

Read more →

Tagrisso (osimertinib) receives US FDA full approval

31 March 2017 - Approval based on Phase III AURA3 trial that demonstrated significant improvement in progression-free survival with Tagrisso as ...

Read more →

FDA approves expanded indication for Qudexy XR (topiramate) extended release capsules to include prophylaxis of migraine headache in adults and adolescents

30 March 2017 - Molecule most prescribed by neurologists for migraine prophylaxis now available in a unique 24 hour formulation. ...

Read more →

FDA: helping small businesses get big results

30 March 2017 - It is well known that small business is vital to the success of the American economy. Less ...

Read more →